Personalizing ADT Across the Prostate Cancer Spectrum

madman · Jan 23, 2025

"What is the role of androgen deprivation therapy (ADT) in prostate cancer treatment? In this episode of the BackTable Urology Podcast, Dr. Rana McKay, a medical oncologist from UC San Diego, joins host Dr. Aditya Bagrodia to discuss the administration of ADT and other management strategies for prostate cancer.

SYNOPSIS

The doctors offer a historical perspective into the evolution of ADT over time and discuss the variety of different ADT treatment options available. They compare management strategies for localized and metastatic prostate cancer and discuss how to align therapy with patient goals, focusing on the side effects. The conversation also explores the impact of prostate-specific membrane antigen (PSMA) PET imaging on management and the future directions of hormonal therapies in urologic oncology.

TIMESTAMPS

00:00 - Introduction
05:25 - ADT Options
10:36 - Choosing an Agent and Managing Side Effects
26:42 - Continuous Versus Intermittent Therapy
30:30 - Closing Remarks

madman · Jan 23, 2025

Thread 'Testosterone recovery after ADT in localised prostate cancer'

Apr 8, 2024

Background and purpose

To determine the rate and time of testosterone (T) recovery in patients (pts) with localised prostate cancer treated with radiotherapy plus 0-, 6-, 18- or 36-month of androgen deprivation therapy (ADT).Materials and methods In 1230 pts with prostate cancer randomised into two phase III trials, serum T was measured at baseline, then regularly.T recovery rate was compared between normal vs. abnormal baseline T and with ADT duration with Chi-square test or Fisher's exact test. A multivariable logistic regression model to predict the probability of recovering...